your shortcut to biotech decision-makers
Get a Verified Biotechnology Email List in Seconds
Reach VPs of R&D, Heads of Discovery, CSOs, clinical development leads, and BD&L directors across therapeutics, genomics, cell and gene therapy, synthetic biology, and life-science tools makers. Access 852M+ verified contacts, only pay for what's verified.
Priya Menon
VP R&D · Moderna
Daniel Hsu
Head of Discovery · Vertex Pharmaceuticals
Adaeze Okoye
Chief Scientific Officer · Beam Therapeutics
Lars Krause
VP Clinical Development · Illumina
Trusted by 25,000+ businesses worldwide
Why prospect Biotechnology
Biotech buys on milestones, buys by committee, and buys to move the pipeline
The US biotechnology sector is a roughly $699B market spread across nearly 150,000 bioscience establishments, and a single platform deal, assay rollout, or IND-enabling study can put 7 or more stakeholders on one purchase. VPs of R&D, Heads of Discovery, CSOs, clinical development leads, and process development directors buy reagents and antibodies, sequencing and instruments, CRO and CDMO services, lab informatics, and CRISPR and assay platforms to advance candidates from discovery to the clinic. Saleshandy gives you a verified biotechnology email list of the decision-makers behind those buying committees, in real time.
$699B
US biotechnology market, 2025
~150K
US bioscience establishments
428K
US biotechnology workers
7-9
stakeholders per platform buy
Decision-makers to target
Buying signals to filter on
520K+
Biotechnology contacts
75+
Search filters
30+
Data fields per contact
98%
Avg. verification rate
What you get
What's inside your biotechnology email list
Every contact in your biotechnology email list ships with verified emails, direct dials, and 30+ data fields, mapped to sub-vertical and funding stage where relevant, verified across 9 trusted sources.
| Name | Title | Company | Sub-vertical | Headcount | Revenue | Funding | ||
|---|---|---|---|---|---|---|---|---|
| Priya Menon | VP of R&D | Moderna | Therapeutics (mRNA) | 5,600 | $3.2B | Public | p.menon@modernatx.com | |
| Daniel Hsu | Head of Discovery | Vertex Pharmaceuticals | Therapeutics | 5,000 | $9.9B | Public | d.hsu@vrtx.com | |
| Rohan Bhatt | VP of R&D | Regeneron Pharmaceuticals | Therapeutics (mAb) | 12,000 | $13.1B | Public | r.bhatt@regeneron.com | |
| Sofia Larsson | Chief Scientific Officer | Genmab | Therapeutics (mAb) | 2,200 | $2.8B | Public | s.larsson@genmab.com | |
| Marcus Avila | Head of Discovery | Alnylam Pharmaceuticals | Therapeutics (RNAi) | 2,000 | $2.3B | Public | m.avila@alnylam.com |
How it works
Get verified biotechnology contacts in three simple steps
Sign up for free
Create your account and get up to 50 free credits. No credit card required.
Find your exact audience
Type what you need and Sage, our AI, translates it into a precise search. Or layer 75+ filters yourself: biotechnology sub-vertical, headcount, revenue, hiring signals, tech stack, and more.
“Find heads of discovery and directors of process development at US cell and gene therapy companies with $100M+ in funding”
Get verified contacts
Verified emails, direct dials, and 30+ data fields per biotechnology decision-maker, checked across 9 providers in real time. Only pay for verified results.
Reach the right biotech companies & decision-makers
Build your biotechnology email list from a database of 42M companies and 852M verified contacts. Filter by sub-vertical, funding stage, job role, department, location, buying signals, and more.
Find VPs of R&D and Heads of Discovery at US clinical-stage biotechs with 200+ employees
Filters used
Priya Menon
VP of R&D · Moderna
Daniel Hsu
Head of Discovery · Vertex Pharmaceuticals
Rohan Bhatt
VP of R&D · Regeneron Pharmaceuticals
Sofia Larsson
Chief Scientific Officer · Genmab
Marcus Avila
Head of Discovery · Alnylam Pharmaceuticals
The honest pitch
Most biotechnology lists go stale fast. We verify every contact as you search.
Biotechs reorganize after every raise, scientists move between programs and startups, and titles shift the moment a candidate moves from discovery into the clinic. We verify every contact as you search, so you don't reach outdated records.
No credit card · 7-day free trial · Cancel anytime
From list to reply
Building the biotechnology email list is the easy part
Verified data gets you to the right inbox. Getting a reply from a VP of R&D, Head of Discovery, or CSO, people who run programs, not inboxes, takes a little more. Three things move the needle.
Get Up to 50 Biotech Emails Free- PMVerified
Priya Menon
VP R&D · Moderna
- DHVerified
Daniel Hsu
Head of Discovery · Vertex Pharmaceuticals
- AOVerified
Adaeze Okoye
Chief Scientific Officer · Beam Therapeutics
- LKVerified
Lars Krause
VP Clinical Development · Illumina
↓ three things that actually move the needle
- 01
Time it around milestones
A cold email sent at a random time is easy to ignore. But if you reach out right after a biotech closes a Series B, files an IND, or signs a platform deal with a pharma partner, your message lands when budgets open and teams scale. These events are public and easy to track. Reach out in the first few weeks after the news, while priorities are still forming.
- 02
Start with their science
R&D and discovery leaders spot a generic pitch instantly. Use details like their sub-vertical, pipeline stage, lead modality (mAb, CRISPR, mRNA), and recent funding to show you understand the program. Focus on outcomes like cutting assay turnaround or shortening IND-enabling timelines, not your feature list. One specific sentence is more effective than a long pitch.
- 03
Use more than email
Don't rely on email alone. With verified direct dials and LinkedIn profiles, you can reach scientists and BD&L leaders across more than one channel. A CSO who ignores your email may still take a call or accept a LinkedIn request between meetings. Combining email, phone, and LinkedIn consistently improves response rates over any single channel on its own.
More industry lists
Selling into a different industry?
Customer reviews
Teams winning Biotechnology accounts with Saleshandy
Real feedback from teams using Saleshandy to grow their pipeline.
92%
email verification rate
“We pulled 3,000 contacts for a campaign — 92% of emails verified on first try. The data accuracy is unreal. Nothing else we've used comes close.”
Thomas Foley
Founder · HighTouch
23%
higher accuracy vs Apollo
“We ran a side-by-side test vs Apollo and ZoomInfo. Saleshandy Lead Finder had 23% higher email accuracy and cost us a fraction of the price. Switched our entire team over.”
Gareth Hayter
Founder & CEO · Slyce Software Ltd
3%
bounce rate (down from 12%)
“Lead Finder gives me real-time verified emails — not stale data from 6 months ago. My team's bounce rate dropped from 12% to under 3%.”
Julia M.
Director of Sales · Small Business
1,713+ verified reviews across platforms
Biotechnology email list FAQs
Reveal Up to 50 Free Biotechnology Contacts
No credit card · 7-day free trial